Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
US11827910B2 · kind B2 · utility
0Cited by
65References
23Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 5, 2021 |
| Grant date | Nov 28, 2023 |
| Priority date | — |
| Expiry date | Feb 17, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2810/85
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Methods, systems, compositions and strategies for the delivery of WW domain-containing fusion proteins into cells in vivo, ex vivo, or in vitro via ARMMs are provided. Methods, systems, compositions and strategies for the delivery of Cas9 proteins and/or Cas9 variants into cells in vivo, ex vivo, or in vitro via fusion to ARMM associated proteins (e.g., ARRDC1 or TSG101) are also provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.